Anavex Life Sciences Corp (AVXL)

[falconer66a]

Now, or then?

I’d rather suffer paper losses now than risk not owning any stock when there’s a surprise PR one morning that the FDA has approved the drug for Rett, etc.

Gator, thanks. You’ve spoken for a larger number of us with long-term AVXL positions; as opposed to the quick-buck in-and-out crowd.

Generally, those of us who post on this board fall into one of three general categories. One, the short-term trade to gain group. Two, the long-term investment group, who see that their AVXL positions will be very profitable in several years, after the FDA grants approval for at least one CNS disease. Three, the bad-management naysayers lambasting the CEO.

Personally, I can’t comment on the quick-trade group; it’s not what I do in the stock market. I have no expertise or confidence it that scenario. Postings on such have no relevance to me, so I click on the next posting. For those who successfully engage in trading AVXLs, congratulations.

Same for the bad management postings. Those have no relevance to my AVXL investment perspective. Missling doesn’t create Phase 3 clinical trial results. They come from the trials themselves, not by some managerial edict by the CEO.

But many, probably most who have AVXL holdings and read the daily postings on this informative message board have taken into account two considerations. First, Anavex is a biotech start-up, with novel, yet to be proven (Phase 3 clinical results) data; but supported by extremely strong pre-clinical data, in both murines and humans. Therefore, we’ve taken our AVXL positions knowing there is a slight possibility that something untoward might eventually turn up and terminate the company. Therefore, we’ve invested dollars we can afford to lose.

Very likely, however, the clinical results from the three big trials, Rett, Parkinson’s disease dementia, and Alzheimer’s, will be overwhelmingly positive. With those, in a few years, Anavex Life Science Corp will become a major pharmaceutical. In five to ten years, our moderate AVXL positions will have appreciated by orders of magnitude. We can patiently wait.